PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28252266
OWN - NLM
STAT- MEDLINE
DA  - 20170302
DCOM- 20170303
LR  - 20170308
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 376
IP  - 9
DP  - 2017 Mar 02
TI  - Adjuvant Sunitinib in Renal-Cell Carcinoma.
PG  - 893
LID - 10.1056/NEJMc1616636 [doi]
FAU - Zhang, Sheng
AU  - Zhang Sh
AD  - Fudan University Shanghai Cancer Center, Shanghai, China [email protected]
LA  - eng
PT  - Letter
PT  - Comment
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
SB  - AIM
SB  - IM
CON - N Engl J Med. 2016 Dec 8;375(23 ):2246-2254. PMID: 27718781
CIN - N Engl J Med. 2017 Mar 2;376(9):893. PMID: 28249133
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Humans
MH  - Indoles/therapeutic use
MH  - Kidney Neoplasms/drug therapy
MH  - Pyrroles/*therapeutic use
EDAT- 2017/03/03 06:00
MHDA- 2017/03/04 06:00
CRDT- 2017/03/03 06:00
AID - 10.1056/NEJMc1616636 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 Mar 2;376(9):893. doi: 10.1056/NEJMc1616636.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>